PMID- 21631401
OWN - NLM
STAT- MEDLINE
DCOM- 20120203
LR  - 20191027
IS  - 1996-3181 (Electronic)
IS  - 1871-5273 (Linking)
VI  - 10
IP  - 5
DP  - 2011 Aug
TI  - Dendrimers as novel systems for delivery of neuropharmaceuticals to the brain.
PG  - 576-88
AB  - Most of the newly developed drugs fails to achieve sufficient bioavailability in 
      to brain due to low water solubility and low permeability. Drug delivery systems 
      are one method for achieving entry of molecules to their desired site of action 
      within the body. Dendrimers are the customizable nanopolymers with uniform and 
      well-defined particle size and shape. Dendrimers are of eminent interest for 
      biomedical applications because of their ability to cross cell membranes. This 
      potential pharmaceutical delivery system crosses the blood brain barrier (BBB) 
      and other important target points. The high level of control over the dendritic 
      architecture (size, branching density, surface functionality) make dendrimers 
      ideal carriers in the field of brain drug delivery of anticancer, 
      antiinflammatory, and antimicrobial agents. Examples of dendrimers such as 
      poly(amidoamine) (PAMAM), poly(propylene imine) (PPI) and polyether-copolyester 
      (PEPE), Glyco, PEGylated, peptide and pH dendrimers are of outmost significance. 
      These dendrimers carry the drug molecules by physical interactions 
      (encapsulation) or through chemical bonding (prodrug approach), while pH 
      sensitive dendrimers are able to deliver drug molecules by alteration of ionic 
      exchange in the brain microenvironment at the tumor site. Techniques employing 
      dendrimers could be especially useful for drugs targeting to Alzheimer's and 
      Prion's diseases. The present review should be of value to scientists who wish to 
      work on the dendrimers for the delivery of molecules into the brain by systemic 
      dosing.
FAU - Beg, Sarwar
AU  - Beg S
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, Hamdard Nagar, 
      New Delhi, India.
FAU - Samad, Abdus
AU  - Samad A
FAU - Alam, M I
AU  - Alam MI
FAU - Nazish, Iram
AU  - Nazish I
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - CNS Neurol Disord Drug Targets
JT  - CNS & neurological disorders drug targets
JID - 101269155
RN  - 0 (Central Nervous System Agents)
RN  - 0 (Dendrimers)
RN  - 0 (Drug Carriers)
SB  - IM
MH  - Animals
MH  - Blood-Brain Barrier/physiology
MH  - Brain/drug effects/*physiology
MH  - Brain Diseases/*drug therapy/physiopathology
MH  - Central Nervous System Agents/chemistry/metabolism/*pharmacology/therapeutic use
MH  - Dendrimers/chemistry/*metabolism/pharmacology
MH  - Drug Carriers/chemistry
MH  - *Drug Delivery Systems
MH  - Humans
EDAT- 2011/06/03 06:00
MHDA- 2012/02/04 06:00
CRDT- 2011/06/03 06:00
PHST- 2010/08/27 00:00 [received]
PHST- 2010/11/15 00:00 [accepted]
PHST- 2011/06/03 06:00 [entrez]
PHST- 2011/06/03 06:00 [pubmed]
PHST- 2012/02/04 06:00 [medline]
AID - BSP/CDTCNSND/E-Pub/00138 [pii]
AID - 10.2174/187152711796235023 [doi]
PST - ppublish
SO  - CNS Neurol Disord Drug Targets. 2011 Aug;10(5):576-88. doi: 
      10.2174/187152711796235023.